Published on
May 9, 2022

Clearmind Strengthens its Scientific Advisory Board With Substance Abuse and Mental Health Professionals

Prof. Schütz’ main research interests focus on clinical interventions and health service in substance use disorders and mental health diagnoses; Prof. Weiser specializes in psychiatric disorders such as substance abuse and depression.

TORONTO, May 09, 2022 (GLOBE NEWSWIRE) --  Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the "company"), an intellectual property driven pharmaceutical company focused on the discovery and development of new, atypical-psychoactive therapies to solve major undertreated health problems, today announced the appointment of two new members to its Scientific Advisory Board (“SAB”). Prof. Christian G. Schütz MD PhD MPH FRCPC, of the University of British Columbia, Canada and Prof. Mark Weiser, MD, Chairman of Dept of Psychiatry at Sackler School of Medicine, and head of the Psychiatric Division at Sheba Medical- Center, Israel.

Prof. Schütz, an Associate Professor at the Department of Psychiatry in the university’s Faculty of Medicine, focuses on clinical interventions and health service in substance use disorders and dual diagnoses (mental and substance use disorders), as well as neurobiological and neurocognitive aspects of impulsive decision-making. His main research focuses on understanding mechanisms of relapse and impulsive decision-making to improve treatment of addiction and concurrent disorders. He has published over 100 research articles and a dozen chapters.

Prof. Weiser, head of the Psychiatric Division at Sheba Medical Hospital, specializes, among others, in cognitive impairment in persons with psychiatric disorders such as substance abuse, depression and personality disorders.

“Clearmind continues to receive substantial validation with leading experts from all around the world joining our Scientific Advisory Board, said Clearmind CEO, Dr. Adi Zuloff- Shani. “Prof. Schütz and Prof. Weiser have extensive experience with research, clinical trials as well as treating patients suffering from mental disorders and substance abuse. We are honored by their motivation to contribute to Clearmind by joining the company's SAB and are excited by their expected contribution to Clearmind.”

About Clearmind Medicine Inc.

Clearmind is an intellectual property driven pharmaceutical company focused on the discovery and development of new, atypical-psychoactive therapies to solve widespread and underserved psychiatric disorders such as addictions, including alcohol use disorder and depression. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of four patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol "CMND", the Frankfurt Stock Exchange under the symbol “CWYO” and on the OTC Markets under the symbol "CMNDF".

For further information, please contact:
Investor Relations,
Telephone: (604) 260-1566
General Inquiries,


This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company's business strategy. There is no certainty that any of these events will occur. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.